Cargando…
Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381765/ https://www.ncbi.nlm.nih.gov/pubmed/37511848 http://dx.doi.org/10.3390/life13071473 |
_version_ | 1785080524942868480 |
---|---|
author | Amalia, Muttia Puteri, Meidi Utami Saputri, Fadlina Chany Sauriasari, Rani Widyantoro, Bambang |
author_facet | Amalia, Muttia Puteri, Meidi Utami Saputri, Fadlina Chany Sauriasari, Rani Widyantoro, Bambang |
author_sort | Amalia, Muttia |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely than those without T2DM, mainly due to an increased risk of atherosclerosis. The rupture of an atherosclerotic plaque leading to pathological thrombosis is commonly recognized as a significant factor in advancing cardiovascular diseases caused by TD2M, with platelets inducing the impact of plaque rupture in established atherosclerosis and predisposing to the primary expansion of atherosclerosis. Studies suggest that individuals with T2DM have platelets that display higher baseline activation and reactivity than those without the condition. The expression enhancement of several platelet receptors is known to regulate platelet activation signaling, including platelet glycoprotein-Ib (GPIb). Furthermore, the high expression of platelet GP1b has been reported to increase the risk of platelet adhesion, platelet-leucocyte interaction, and thrombo-inflammatory pathology. However, the study exploring the role of GP1b in promoting platelet activation-induced cardiovascular diseases in T2DM patients is still limited. Therefore, we summarize the important findings regarding pathophysiological continuity between T2DM, platelet GPIb, and atherosclerosis and highlight the potential therapy targeting GPIb as a novel antiplatelet agent for preventing further cardiovascular incidents in TD2M patients. |
format | Online Article Text |
id | pubmed-10381765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103817652023-07-29 Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients Amalia, Muttia Puteri, Meidi Utami Saputri, Fadlina Chany Sauriasari, Rani Widyantoro, Bambang Life (Basel) Review Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition that contributes to the development of cardiovascular diseases. Numerous studies have provided evidence that individuals with T2DM are at a greater risk of developing cardiovascular diseases, typically two to four times more likely than those without T2DM, mainly due to an increased risk of atherosclerosis. The rupture of an atherosclerotic plaque leading to pathological thrombosis is commonly recognized as a significant factor in advancing cardiovascular diseases caused by TD2M, with platelets inducing the impact of plaque rupture in established atherosclerosis and predisposing to the primary expansion of atherosclerosis. Studies suggest that individuals with T2DM have platelets that display higher baseline activation and reactivity than those without the condition. The expression enhancement of several platelet receptors is known to regulate platelet activation signaling, including platelet glycoprotein-Ib (GPIb). Furthermore, the high expression of platelet GP1b has been reported to increase the risk of platelet adhesion, platelet-leucocyte interaction, and thrombo-inflammatory pathology. However, the study exploring the role of GP1b in promoting platelet activation-induced cardiovascular diseases in T2DM patients is still limited. Therefore, we summarize the important findings regarding pathophysiological continuity between T2DM, platelet GPIb, and atherosclerosis and highlight the potential therapy targeting GPIb as a novel antiplatelet agent for preventing further cardiovascular incidents in TD2M patients. MDPI 2023-06-29 /pmc/articles/PMC10381765/ /pubmed/37511848 http://dx.doi.org/10.3390/life13071473 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Amalia, Muttia Puteri, Meidi Utami Saputri, Fadlina Chany Sauriasari, Rani Widyantoro, Bambang Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title | Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title_full | Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title_fullStr | Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title_full_unstemmed | Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title_short | Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients |
title_sort | platelet glycoprotein-ib (gpib) may serve as a bridge between type 2 diabetes mellitus (t2dm) and atherosclerosis, making it a potential target for antiplatelet agents in t2dm patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381765/ https://www.ncbi.nlm.nih.gov/pubmed/37511848 http://dx.doi.org/10.3390/life13071473 |
work_keys_str_mv | AT amaliamuttia plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients AT puterimeidiutami plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients AT saputrifadlinachany plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients AT sauriasarirani plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients AT widyantorobambang plateletglycoproteinibgpibmayserveasabridgebetweentype2diabetesmellitust2dmandatherosclerosismakingitapotentialtargetforantiplateletagentsint2dmpatients |